Earnings
The agreement between the two companies includes a lead, potential first-in-class preclinical candidate, and research collaboration to jointly develop the additional novel candidates.
Arc begins its mission with $650 million in donations from donors. This funding will sustain the scientists and their researchers over renewable eight-year terms.
Nodexus and Aramis Biosciences will use their funds to expand their company’s pipeline and build their commercialization capabilities.
Generation Bio’s stock plummeted 54% to $6.35 yesterday after it reported in an SEC filing that its hemophilia A therapy data in mice couldn’t be duplicated in non-human primate studies.
The collaboration covers the co-development and co-commercialization of products created from Foghorn’s BRM oncology program and another oncology target.
The cash came rolling in for four biopharma companies Thursday morning, with collective Series A rounds totaling more than $125 million.
Biopharmaceutical firm Alvotech Holdings announced merger plans with Oaktree Acquisition Corp. in a deal that will create a combined entity worth around $2.25 billion.
Ionis will manufacture and supply the drug for ongoing trials and process qualifications, while AstraZeneca will handle the commercial supply of eplontersen.
NanoMosaic plans to use the funds raised to continue building its commercial infrastructure, developing its applications, and advancing diagnostic collaborative development programs.
With this new collaboration, Astellas will take advantage of Dynos’ next-gen AAV vectors to deliver its gene therapy.
PRESS RELEASES